Agreement with Maquet Australia Pty Ltd for the supply of interventional cardiology devices
PHARMAC is pleased to announce the approval of an agreement with Maquet Australia Pty Ltd (“Maquet”) for the supply of Interventional Cardiology devices.
In summary, the effect of the decision is that:
- A range of Interventional Cardiology devices will be listed in section H, Part III, ('Optional Pharmaceuticals') of the Pharmaceutical Schedule for 1 November 2015.
- DHB hospitals can purchase these items either directly from Maquet or through a designated third party logistics provider under the national agreement.
- For the DHBs that currently use these products the national agreement will deliver savings.
Details of the decision
Following a Registration of Interest document issued in April 2014, PHARMAC has entered into an agreement with Maquet for the supply of a selection of Interventional Cardiology devices to be listed on the Pharmaceutical Schedule. This means that DHB hospitals may purchase these products under the national agreement at the new pricing.
There are estimated savings to DHBs that currently use these products of approximately $18,000 per annum nationally, based on current usage.
The agreement is not exclusive. DHBs can continue to purchase other brands of Interventional Cardiology devices at their discretion.
Educational services will be provided by Maquet to DHB personnel on appropriate use of its Interventional Cardiology devices and will be arranged in a format and times as agreed with individual DHBs.
PHARMAC appreciates all of the feedback that it has received and acknowledges the time people took to respond. All consultation responses received by 9 October 2015 were considered in their entirety in making a decision on the proposed changes. No issues were raised in relation to specific aspects of the proposal.
If you have any questions about this decision you can email PHARMAC at email@example.com or call our toll free number (9 am to 5 pm, Monday to Friday) on 0800 66 00 50.